MedPacto Announces Execution of a collaborative study Agreement for ‘Cancer Diagnostic Kit’ with Gangnam Severance Hospital
Apr 08, 2022
Cancer diagnostic kit detecting cancer by measuring the expression level of BAG2 protein in the blood
Gangnam Severance Hospital-SoonChunHyang University Hospital Seoul, practicing a collaborative study using blood samples of healthy people and the patients
January 00, 2022 – MedPacto, Inc (KOSDAQ: 235980), a genome-based drug discovery and clinical-stage biotechnology company, announced that they have entered into a clinical collaboration agreement with Gangnam Severance Hospital and SoonChunHyang University Hospital Seoul to develop cancer diagnostic kit which is able to detect cancer in the blood.
Seong-jin KIM, CEO of MedPacto, identified the mechanism of action for the BAG 2 protein regarding recurrence and metastasis of triple-negative breast cancer for the first time in the medicine. Seong-jin KIM has confirmed that there is a correlation between BAG2 protein and tumorigenicity by confirming an overexpression of BAG2 secreted out of cells in the blood of breast cancer patients when compared to that of healthy people.
The BAG2 Biomarker-based cancer diagnostic kit that MedPacto is currently developing detects cancer by measuring the level of BAG2 expression in the blood.
Imaging diagnosis or biopsy are the major diagnostic tools for cancer diagnosis at this junction. As the cancer diagnostic kit for this clinical trial will detect cancer by measuring the BAG2 level secreted out of cells in the blood, fast prognostic estimation would be available.
The study, led by Dr. Joon Jung of Gangnam Severance Hospital and Dr. HaeIn Bang of SoonChunHyang University Hospital Seoul, is designed to compare the blood samples of existing breast cancer patients at Gangnam Severance Hospital and the blood samples of a healthy population control at SoonchunHyang University hospital Seoul.
MedPacto is now developing a clinical trial sample for the cancer diagnostic kit aiming to start the collaborative study in the first half of this year.
In addition, MedPacto is producing promising research results for antibody therapeutics targeting BAG2, expecting to provide a companion diagnostic kit that can provide a full spectrum of care from diagnosis to treatment.
“This study is to prove the potential for BAG2 to serve as a predictive biomarker to diagnose cancer by comparing BAG2 level of the plasma and serum in the blood of the healthy people and the cancer patients.”
“As MedPacto is currently developing an antibody therapeutics targeting BAG2, we can provide companion diagnostic to stratify and select patients to maximize the therapeutic effects among cancer patients in the future.” stated a MedPacto representative.
MedPacto has signed a CDMO contract with Thermo Fisher Scientific for the cancer diagnostic kit and registered a patent in March 2021.